This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AVEO Pharmaceuticals マネジメント

マネジメント基準チェック /24

主要情報

Michael Bailey

最高経営責任者

US$2.9m

報酬総額

CEO給与比率	20.0%
CEO在任期間	8yrs
CEOの所有権	1.0%
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	8yrs

経営陣の近況

Recent updates

CEO報酬分析

AVEO Pharmaceuticals の収益と比較して、Michael Bailey の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$41m
Dec 31 2021	US$3m	US$590k	-US$53m
Sep 30 2021	n/a	n/a	-US$58m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$2m	US$565k	-US$36m
Sep 30 2020	n/a	n/a	-US$29m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	US$452k
Dec 31 2019	US$2m	US$528k	US$9m
Sep 30 2019	n/a	n/a	US$36m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	US$4m
Dec 31 2018	US$3m	US$528k	-US$5m
Sep 30 2018	n/a	n/a	-US$24m
Jun 30 2018	n/a	n/a	-US$28m
Mar 31 2018	n/a	n/a	-US$65m
Dec 31 2017	US$1m	US$480k	-US$65m
Sep 30 2017	n/a	n/a	-US$74m
Jun 30 2017	n/a	n/a	-US$53m
Mar 31 2017	n/a	n/a	-US$28m
Dec 31 2016	US$1m	US$444k	-US$27m

報酬と市場: Michael's total compensation ($USD2.94M) is above average for companies of similar size in the German market ($USD910.42K).

報酬と収益: Michael's compensation has increased whilst the company is unprofitable.

CEO（最高経営責任者

Michael Bailey (57 yo)

8yrs

在職期間

US$2,943,905

報酬

Mr. Michael P. Bailey serves as an Independent Chairman at IMV Inc. since May 01, 2022 and has been its Independent Director since July 20, 2020. He has been Chief Executive Officer and President of AVEO P...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Michael Bailey	CEO, President & Director	8yrs	US$2.94m	0.98% $ 4.7m
Erick Lucera	Chief Financial Officer	3yrs	US$1.24m	0% $ 0
Michael Ferraresso	Chief Commercial Officer	no data	US$1.25m	0.038% $ 184.2k
Jeb Ledell	Chief Operating Officer	1.1yrs	データなし	0% $ 0
Danielle Holland	VP of Legal & Corporate Secretary	2yrs	データなし	データなし
Kevin Peacock	Senior Vice President of Marketing	3.2yrs	データなし	データなし
David Crist	Vice President of Sales	2.3yrs	データなし	データなし
Catherine DeRose	Vice President of Human Resources	2.3yrs	データなし	データなし
Lisa Bruneau	VP of Finance & Treasurer	7yrs	データなし	データなし

2.7yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: VPA1's management team is considered experienced (2.7 years average tenure).

取締役

名称	ポジション	在職期間	報酬	所有権
Michael Bailey	CEO, President & Director	8yrs	US$2.94m	0.98% $ 4.7m
Anthony Evnin	Independent Director	20.8yrs	US$127.61k	0.12% $ 578.0k
Kenneth Bate	Independent Chairman	15.1yrs	US$158.73k	0.0011% $ 5.2k
Raju Kucherlapati	Member of Scientific Advisory Board	no data	US$3.00k	データなし
Charles Sawyers	Member of Scientific Advisory Board	no data	データなし	データなし
H. Horvitz	Member of Scientific Advisory Board	no data	データなし	データなし
Tyler Jacks	Member of Scientific Advisory Board	no data	データなし	データなし
Lynda Chin	Member of Scientific Advisory Board	no data	データなし	データなし
Lewis Cantley	Member of Scientific Advisory Board	no data	データなし	データなし
Gregory Mayes	Independent Director	3.9yrs	US$120.61k	0% $ 0
Douglas Hanahan	Member of Scientific Advisory Board	no data	データなし	データなし
Scarlett Spring	Independent Director	3.2yrs	US$126.84k	0% $ 0

8.0yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: VPA1's board of directors are considered experienced (8 years average tenure).

This company listing is no longer active

AVEO Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

AVEO Oncology Announces Appointment of Mike Ferraresso to Chief Commercial Officer

AVEO Pharmaceuticals, Inc. Appoints Corinne Epperly as Member of the Board and to Its Nominating and Governance Committee and Compensation Committee

AVEO Pharmaceuticals, Inc. Announces the Departure of Karuna Rubin, Senior Vice President and General Counsel

AVEO Pharmaceuticals, Inc. Announces Management Changes

Recent updates

LG Chem, Ltd. (KOSE:A051910) completed the acquisition of AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO) from a group of shareholders.

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.30 loss in 3Q 2021)

Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022

AVEO Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

AVEO Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.40 loss in 2Q 2021)

AVEO Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell Microcap Value Index

AVEO Oncology Announces Updated National Comprehensive Cancer Network Clinical Practice Guidelines Elevate Fotivda (Tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced Renal Cell Carcinoma Patients

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.81 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AVEO Pharmaceuticals, Inc. Announces Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® in Third- and Fourth-Line Renal Cell Carcinoma

Aveo Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

Aveo Oncology Highlights Recent Progress and 2022 Outlook

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.33 loss in 3Q 2020)

AVEO Oncology Announces Ficlatuzumab Grants Fast Track Designation by the U.S. FDA

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell 3000E Value Index

AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC

CANbridge Life Sciences Ltd. and AVEO Pharmaceuticals, Inc. Terminate Collaboration and License Agreement

AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate Fotivda® in Combination with Opdivo® in Pivotal Phase 3 Tinivo-2 Trial in Io Relapsed Renal Cell Carcinoma

AVEO Oncology Announces U.S. FDA Approval of FOTIVDA (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma

AVEO Oncology Announces Appointment of Mike Ferraresso to Chief Commercial Officer

AVEO Pharmaceuticals, Inc. Appoints Corinne Epperly as Member of the Board and to Its Nominating and Governance Committee and Compensation Committee

AVEO Pharmaceuticals, Inc. Announces the Departure of Karuna Rubin, Senior Vice President and General Counsel

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (Durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

AVEO Pharmaceuticals, Inc. Announces Management Changes

AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc. announced that it has received $7.499997 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24